AIM
CORT icon

Ausbil Investment Management’s Corcept Therapeutics CORT Stock Holding History

Ausbil Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,235
Closed -$356K – 67
2025
Q4 		$356K Buy
10,235
+4,629
+83% +$364K 0.2% 60
2025
Q3 		$472K Buy
+5,606
New +$406K 0.25% 56

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Ausbil Investment Management's CORT Position: Q1 2026 in Review

Ausbil Investment Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 10,235 shares — an estimated $356K sold.

Ausbil Investment Management first reported a position in CORT in Q3 2025 and held it in 2 quarters. The position peaked at $472K in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Ausbil Investment Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ausbil Investment Management sold 10,235 Corcept Therapeutics shares in Q1 2026, an estimated $356K.
  • Ausbil Investment Management first reported a position in Corcept Therapeutics in Q3 2025 and held it in 2 quarters.
  • Ausbil Investment Management's Corcept Therapeutics position peaked at $472K in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Ausbil Investment Management's 13F filing for Q1 2026, filed 8 Apr 2026.